Takeda and Lundbeck announce Brintellix for treatment of MDD
DEERFIELD, Ill. — Takeda Pharmaceuticals U.S.A. and Lundbeck on Tuesday announced the availability of Brintellix (vortioxetine) — a once-daily oral antidepressant for treatment of major depressive disorder in adults — in pharmacies across the United States.
“MDD continues to be a challenging condition to manage, and we are proud to make Brintellix available as a new treatment option for people struggling with major depression,” said Douglas Cole, president of Takeda Pharmaceuticals U.S.A.
The clinical trial evaluating the safety and efficacy of the drug was comprised of seven studies, including six- to eight-week short-term studies and one 24- to 64-week long-term maintenance study that demonstrated significant improvements in overall symptoms of depression in adults with MDD, according to the companies.
“Our passion for helping people living with MDD has been the inspiration for advancing Brintellix from the laboratory through clinical studies, and now into the hands of those who need it,” said Staffan Schüberg, president of Lundbeck U.S. “This same passion fuels our ongoing commitment to supporting people with this often chronic and complex disease.”
Mission Pharmacal publishes ‘ABCs of Medical Management of Stones’ as an Apple app
SAN ANTONIO — Mission Pharmacal Co. on Tuesday announced its “ABCs of Medical Management of Stones,” a step-by-step approach to the diagnosis and treatment of nephrolithiasis, or kidney stones, is now available as a mobile application for Apple devices.
“The ABCs of Kidney Stones app may simplify an otherwise complicated diagnosis, guiding the physician through the process using a standard protocol that differentiates between first-time and recurrent stone formers,” stated Dan Crawford, marketing director of the Urological Division of Mission Pharmacal Company. “The app provides an interactive and updated version of the popular ABCs literature, which was developed and co-authored by some of the most respected and recognized thought leaders in the management of kidney stones. Their reputations alone add tremendous credibility to this app.”
The ABCs of Medical Management of Stones, now in its second edition, was recently updated by co-authors Margaret Pearle, Glenn Preminger, David Goldfarb and Donald Griffith, with additional input from Charles Pak, for physicians who were looking for an efficient way to manage the complexities of stone disease. “First with the booklet, and now with the app, the ABCs make the doctors’ job easier. The app will get the ABCs into the hands and pockets of younger physicians or those who prefer to get information electronically,” Crawford said.
The app also will allow physicians to show videos to their patients during a visit with topics including how a kidney stone is formed.
The ABCs of Medical Management of Stones was initially released on iTunes for use on Apple devices because at least 60% of physicians now use an iPad tablet in their practices.
The app will be released for use on an Android platform in coming months.
Avion Pharmaceuticals launches prescription supplements Prenate Enhance and Prenate Restore
ATLANTA — Avion Pharmaceuticals on Tuesday announced the launch of two advanced vitamin formulations as the newest additions to the Prenate Vitamin Family — Prenate Enhance and Prenate Restore.
The new prescription supplements have been designed to support important nutritional supplementation for women during their prenatal and postpartum period, as well as provide the optimal level of vitamins and minerals recommended.
"Avion is excited to be a leader in innovation for the women’s health category by providing two new prescription supplements that have been formulated based on expert recommendations for nutritional supplementation for women both pregnant and postpartum," stated Mike Sullivan, VP sales and marketing for Avion Pharmaceuticals. "Prenate Enhance and Prenate Restore were designed for nutritional support for both moms and babies during this important period in their life."
Prenate Enhance and Prenate Restore are advanced prescription dietary supplements designed for enhanced absorption with ingredients selected for their high absorbability.
Prenate Restore, the first prescription postnatal dietary supplement with probiotics, designed for postpartum supplementation, helps support the needs of both moms and babies post-pregnancy when nutritional stores can often be depleted.
Prenate Enhance and Prenate Restore provide the highest DHA content (400 mg) among leading prescription prenatal and postnatal vitamins, according to the company, and also include Formical (calcium formate), a patented form of calcium that is better absorbed than calcium citrate and calcium carbonate. And both products provide proprietary Quatrefolic, a source of folate that is approximately seven times more bioavailable than folic acid.